Kiniksa Pharmaceuticals International (KNSA) Cash & Current Investments (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Cash & Current Investments for 10 years, with the latest figure at $468.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 23.33% year-over-year to $468.1 million; the trailing twelve-month figure through Mar 2026 stood at $468.1 million (up 23.33% YoY), and the FY2025 full-year result was $414.1 million, up 69.96% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $468.1 million, up from $414.1 million in the prior quarter.
• The five-year high for Cash & Current Investments was $468.1 million in Q1 2026, with the low at $182.1 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $278.3 million across 5 years, with a median of $243.6 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments sank 35.83% — and 2024, when it surged 82.84%.
• Kiniksa Pharmaceuticals International's Cash & Current Investments stood at $190.6 million in 2022, then increased by 8.27% to $206.4 million in 2023, then increased by 18.05% to $243.6 million in 2024, then surged by 69.96% to $414.1 million in 2025, then rose by 13.05% to $468.1 million in 2026.
• The last three Cash & Current Investments figures came in at $468.1 million (Q1 2026), $414.1 million (Q4 2025), and $352.1 million (Q3 2025), per Business Quant data.